ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $11.71M rose 48.0% year over year, ahead of the +30.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 10.4% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.
Context
- Selling, general & admin amounted to 89.1% of revenue in FY2025, up 4.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $44.7M (+35.6%) for the fiscal year ending Dec 2026, a step up from the +24.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.71M+10.4% QoQ
- Last fiscal yearDec 2025
- $32.96M+24.5% YoY
- LTMMar 2026
- $36.76M+30.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 32.96M USD
- Year-over-year change
- +24.5%
- 4-year CAGR
- +21.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.96M | +24.5% |
| FY2024 | 2024-12-31 | 26.48M | +8.7% |
| FY2023 | 2023-12-31 | 24.35M | +28.4% |
| FY2022 | 2022-12-31 | 18.97M | +24.7% |
| FY2021 | 2021-12-31 | 15.22M | — |
Selling, General & Admin vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.1% is the 2nd highest of 10, against a peer median of -0.5%.
- Selling, general & admin amounts to 90.5% of revenue for CLPT, versus a peer median of 52.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $555.96M USD | +4.1% | +13.9% | 67.4% | |
| LTM Mar 2026 | $290.1M USD | -3.4% | -12.3% | 40.5% | |
| LTM Mar 2026 | CA$210.35M CAD | -3.8% | +10.0% | 22.4% | |
| LTM Mar 2026 | $166.97M USD | +8.5% | +6.4% | 81.0% | |
| LTM Apr 2026 | $135.6M USD | -0.5% | +4.1% | 15.8% | |
| LTM Mar 2026 | $113.08M USD | +20.7% | +16.9% | 55.4% | |
| LTM Mar 2026 | $113.07M USD | +41.5% | -8.1% | 48.7% | |
| LTM Mar 2026 | $97.69M USD | -22.9% | +2.4% | 113.3% | |
| LTM Mar 2026 | $58.26M USD | -9.3% | +10.1% | — | |
| LTM Mar 2026 | $36.76M USD | +30.1% | +20.2% | 90.5% | |
| Peer median (excluding CLPT) | — | -0.5% | +6.4% | 52.0% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.